1. Introduction {#s0005}
===============

OSCC is one of the most common HNSCC, with an estimated 260,000 new cases and 120,000 deaths worldwide each year ([@bb0005]). Despite recent advances in diagnosis and treatment, the 5-year survival rate of patients with OSCC is no more than 50% ([@bb0010]). Over the past two decades, numerous prognostic and predictive markers for clinical outcomes in OSCC have been proposed ([@bb0015]); however, few have been applied in clinical practice due to the non-reproducibility of the initial findings ([@bb0020], [@bb0025]). To date, the classical clinic pathological parameters of tumor such as primary site, tumor stage, lymph nodal stage and clinical TNM stage remain the most significant factors to affect outcome of patients with OSCC. However, it is impossible to predict patients at a high risk of death mainly based on these parameters. Therefore, it is critical to identify novel and effective prognostic predictors and therapeutic targets for treating this common malignancy.

In eukaryotic cells, proteasomes play an essential role in intracellular proteolysis and are involved in the control of most biological processes through regulated degradation of key proteins. PA28 is a member of a unique family of proteasomal activators that has the ability to stimulate the proteolytic activity of the 20S core proteasome independent of ubiquitination and ATP ([@bb0030]). Unlike PA28α and PA28β, PA28γ (also known as Ki antigen, 11Sγ, or REGγ) localizes in the nucleus and forms a homo-heptamer ([@bb0035], [@bb0040], [@bb0045]). PA28γ, regulated by MEKK3, B-RAF, caspase-3/7 and targeted by miR-7-5p, is a multifunctional protein that is involved in the degradation of important regulatory proteins, such as SRC-3, PTTG1 and cyclin-dependent kinase inhibitors p21/16/19 in an ubiquitin- and ATP-independent manner, and has been implicated in the regulation of cell cycle progression ([@bb0030], [@bb0050], [@bb0055], [@bb0060], [@bb0065]). Moreover, PA28γ-deficient mice have been shown to exhibit growth retardation ([@bb0070]). Several targets of PA28γ have been identified in recent years, suggesting that it plays important roles in angiogenesis, hepatic lipid metabolism, infectious diseases and premature aging ([@bb0075], [@bb0080], [@bb0085], [@bb0090]). PA28γ is over-expressed in some cancer tissues, suggesting that this protein may also have a potential role in tumorigenesis ([@bb0095], [@bb0100]). Some studies found that PA28γ may facilitate the turnover of the tumor suppressor p53 by promoting murine double minute 2 (MDM2)-mediated p53 ubiquitination ([@bb0105], [@bb0110]) and PA28γ could take part in the ATM-DBC1-SIRT1 axis induced p53-dependent apoptosis ([@bb0115]). Recently researchers found that mutant p53 (p53-R248Q) could up-regulate PA28γ in endometrial cancer ([@bb0120]), thus, there is an auto-regulatory feedback loop between p53 and PA28γ ([@bb0125]). Nevertheless, the mechanism by which PA28γ exerts its effects on tumor cells remains unclear.

In our previous study, we conducted a comprehensive proteomic analysis to identify candidate biomarkers in OSCC ([@bb0130]). Expression levels of 52 proteins in OSCC tumor tissues were significantly different from those in normal tissues ([@bb0135]). One of these proteins was PA28γ. The bioprocesses and interaction network analysis indicated that PA28γ might play an important role in malignant transformation. Given these findings, we hypothesized that PA28γ may be involved in malignant development and progression of OSCC and would have effect on the prognosis of this disease. To test this hypothesis, we first explored the protein expression profile of PA28γ and its relations with the outcome of OSCC patients in three independent cohorts from two centers. Then, we constructed models to predict death of patients with OSCC using PA28γ individually and jointly with other prognostic factors identified in these three cohorts. Finally, we investigated the effects of PA28γ on the biological behavior of OSCC cells both in vitro and in vivo.

2. Methods and patients {#s0025}
=======================

2.1. Patients {#s0030}
-------------

The Institutional Review Boards of the West China Hospital of Stomatology, Sichuan University and Guangdong Provincial Stomatological Hospital approved this study. The study was approved by the ethics committee both of the West China Hospital of Stomatology and the Guangdong Provincial Stomatological Hospital and was conducted in agreement with the Helsinki Declaration. Written informed consent was provided by all participants at baseline and during follow-up.

A total of 368 postoperative patients with primary OSCC tumors received regular follow-up. Follow-up visits entailed at least a medical history and clinical examination. In addition to scheduled visits, all patients could initiate visits if they were concerned that they had recurrence or a new primary tumor. The survival time of each patient was calculated from the day of surgery until the time of cancer-related death or the end of the follow-up period, death for other reasons led to censoring of data. The detailed information of three cohorts was described in Supplemental Patients and Methods.

An independent cohort of 460 patient specimens obtained between 1992 and 2013 in the TCGA database (<http://tcga-data.nci.nih.gov/tcga/>) was used as an external validation cohort to validate the prognostic value of PA28γ in patients with HNSCC ([Table S1](#ec0005){ref-type="supplementary-material"}).

2.2. Laboratory experiments {#s0035}
---------------------------

All animal studies were approved by the Animal Care and Use Committee, State Key Laboratory of Oral Diseases, in compliance with the Guide for the U.S. Public Health Service\'s policy on humane care and use of laboratory animals ([@bb0140]). Animals were housed within 12-h light/dark cycles and received food, standard rodent chow, and water ad libitum in compliance with the Association for Assessment and Accreditation of Laboratory Animal Care International guidelines. Other methods are detailed in Supplemental Patients and Methods including Cell Culture and siRNA transfections, western blot analysis, MTT, colony-formation, propidium iodide (PI) staining, flow cytometry, TUNEL, cell invasion, cell migration, in vivo tumor-formation assay, and immunohistochemistry.

2.3. Statistical analysis {#s0040}
-------------------------

Baseline characteristics among the patients were compared using the mixed linear model for continuous variables and the *χ*^2^ test or Fisher\'s Exact Test for categorical variables. OS and DFS were estimated using the Kaplan--Meier method, with a log-rank test in a univariate analysis. Multivariate survival analysis was done using the Cox proportional hazards model. Model discrimination was measured using C Statistic for survival analysis. Receiver operating characteristic (ROC) curve area was used in the prediction model.

Statistical analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC). Unless stated otherwise, two-sided *P* \< 0.05 were considered significant. Details on data analysis are provided in the Supplementary.

3. Results {#s0010}
==========

3.1. Patient and disease characteristics {#s0045}
----------------------------------------

A total of 368 patients from three independent cohorts (118, 156, and 94 patients in CD-I cohort, CD-II cohort, and GZ cohort, respectively) were included in this study ([Fig. 1](#f0005){ref-type="fig"}). All patients were treated with curative intent. Some of these patients had been treated by radiotherapy and/or chemotherapy. The mean age and gender distribution were comparable across the three cohorts. The median durations of follow-up in the cohorts were 60, 52, and 51 months, respectively. IHC staining showed that PA28γ has a very clear nuclear positive in most tumor but not normal tissues ([Fig. S1](#f0025){ref-type="fig"}). High expression of PA28γ was observed on OSCC cell lines, and in 52.54%, 38.46%, and 60.64% of the patients in the CD-I cohort, CD-II cohort and GZ cohort, respectively ([Table 1](#t0005){ref-type="table"} and [Fig. S2](#f0030){ref-type="fig"}). This finding is consistent with the TCGA database analysis of PA28γ mRNA abundance in human primary oral cancers ([Fig. S3](#f0035){ref-type="fig"}a).

3.2. Univariate and multivariate analyses of PA28γ expression and its predictive value {#s0050}
--------------------------------------------------------------------------------------

In all three cohorts, the results of univariate analysis showed that OS at five years was associated with PA28γ expression ([Table 2](#t0010){ref-type="table"}). For the CD-I cohort, estimated 5-year OS values for patients in the low and high PA28γ expression groups were 84% (95% CI, 0.71--0.91) and 40% (95% CI, 0.28--0.52; [Fig. 2](#f0010){ref-type="fig"}a), respectively. For the CD-II cohort, the estimated 5-year OS values for patients in the low and high PA28γ expression groups were 67% (95% CI, 0.56--0.57) and 28% (95% CI, 0.18--0.40; [Fig. 2](#f0010){ref-type="fig"}b), respectively. For the joint CD-I and CD-II cohorts, the estimated 5-year OS for patients also showed that the risk increased associated with positive staining (*P* \< 0.001; [Fig. 2](#f0010){ref-type="fig"}c). For the GD validation cohort, the estimated 5-year OS values for patients in the low and high PA28γ expression groups were 89% (95% CI, 0.74--0.96) and 57% (95% CI, 0.43--0.69; [Fig. 2](#f0010){ref-type="fig"}d), respectively. Consistent with an external validation cohort of 460 HNSCC patients from the TCGA database analysis in the US population, high PA28γ mRNA was associated with poor survival (*P* = 0.016, [Fig. S3](#f0035){ref-type="fig"}b). Furthermore, the association between PA28γ high expression with lower rates of 5-year Disease-Free Survival (DFS) was also statistically significant in those three independent cohorts (*P* \< 0.001; CD-II: *P* \< 0.001; joint CD-I and -II cohorts: *P* \< 0.001; GD: *P* = 0.004; [Table S2](#ec0010){ref-type="supplementary-material"}; [Fig. S4](#f0040){ref-type="fig"}). Several conventional prognostic factors, including lower cell differentiation, positive nodal stage, higher tumor stage, higher clinical TNM stage and radiotherapy or chemotherapy, were associated with a significantly increased risk of death. History of smoking and alcohol consumption were significantly related with survival (*P* \< 0.005). Some of these factors were included in the multivariable Cox proportional-hazards model and fixed.

Results of the predictive analysis are provided in [Table 3](#t0015){ref-type="table"}. Strong PA28γ expression was independently associated with significantly reduced OSCC patients\' OS in the CD-I cohort (HR, 5.14; 95% CI, 2.51--10.5; *P* \< 0.001) after accounting for smoking history, drinking history, cell differentiation, tumor stage, nodal stage and radiotherapy or chemotherapy; this was later confirmed in the CD-II cohort (HR, 2.82; 95% CI, 1.73--4.61; *P* \< 0.001). There is evidence that patients with PA28γ high expression had worse DFS in the CD-I and CD-II cohorts, with hazard ratios of 3.82 (95% CI, 2.12--6.88; *P* \< 0.001) and 2.96 (95% CI, 1.87--4.69; *P* \< 0.001), respectively ([Table S3](#ec0015){ref-type="supplementary-material"}), after accounting for the same factors as in the OS analysis. Furthermore, in the joint CD-I and CD-II cohorts and in the validation GZ cohort, the analysis results showed similar patterns (*P* \< 0.001; [Table 3](#t0015){ref-type="table"}; [Table S3](#ec0015){ref-type="supplementary-material"}).

3.3. Prediction models for all-cause death of OSCC patients {#s0055}
-----------------------------------------------------------

Multivariable models were constructed for the prediction of all-cause death in OSCC patients by using the combined CD cohort as the discovery cohort, and the GD cohort as a validation cohort. We assessed model discrimination using the C statistic for predictive value and compared the difference between basic models and models including PA28γ expression ([Table S4](#ec0020){ref-type="supplementary-material"}). For the discovery of CD cohort, in Model 1, among the basic risk factors, the C statistic value of PA28γ was highest. The C statistic increased significantly when PA28γ was combined with those conventional risk factors in Models 2 to 4. In Models 3 and 4, when PA28γ was added, the C statistic was larger than 0.75, above which the prediction model is considered relatively good. Similar results were found in the validation GZ cohort. ROC curves were constructed for the mode Models 3 and 4, in which the area under the ROC curve indicates the C statistic ([Fig. 3](#f0015){ref-type="fig"}, [Fig. S5](#f0045){ref-type="fig"}).

3.4. Validation the functional role of PA28γ both in vitro and in vivo {#s0060}
----------------------------------------------------------------------

On the basis of the clinical findings described above, we evaluated the effect of PA28γ on OSCC cell lines and xenograft models. We hypothesized that PA28γ might act as a tumor promoter. If so, PA28γ silencing should reverse some of the early processes of tumorigenesis. PA28γ silencing in both OSCC cell lines caused decreased cell viability and colony growth ([Fig. S6](#f0050){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}a). However, this silencing had no such effect on HOK cells. A significant induction of apoptosis was observed after treatment of cells with PA28γ-specific siRNA ([Fig. 4](#f0020){ref-type="fig"}b). Similar results were also observed in the TUNEL assay ([Fig. S7](#f0055){ref-type="fig"}). These results suggest that PA28γ silencing can inhibit cell proliferation via induction of apoptosis in OSCC cells. Moreover, our data suggested that PA28γ silencing could inhibit the migration and invasion of OSCC cells in vitro ([Fig. S8](#f0060){ref-type="fig"}).

We further investigated whether PA28γ silence could inhibit tumor growth in vivo. OSCC cells treated with PA28γ siRNA modified with 2ʹ OMe and 3ʹ Chol (PA28γ-si group) which have a high effective interference ([Fig. 4](#f0020){ref-type="fig"}c), scramble siRNA (NS-si group) or PBS (CTRL group) were transplanted subcutaneously on the right back of BALB/c nude mice. Tumor growth in the PA28γ-si group was much slower than the other two groups. There was a 40--50% reduction in the average tumor volume in the PA28γ-si group ([Fig. 4](#f0020){ref-type="fig"}d, e). To investigate the potential mechanisms underlying the effects of PA28γ silencing in vivo, we examined tumor cell proliferation, microvessel density (MVD) [@bb0145], and tumor cell apoptosis. As shown in [Fig. S9](#f0065){ref-type="fig"}, dramatic reductions in PCNA expression and tumor angiogenesis and significant increases in TUNEL-positive nuclei were found in the tumors in the PA28γ-si group compared with those in the other two groups.

4. Discussion {#s0015}
=============

In the current study, our results showed that the proteasomal activator PA28γ is a prognostic biomarker in OSCC with higher expression levels correlating with worse outcomes compared with normal tissues. We studied three cohorts from China and found consistent results supporting a pronounced effect of PA28γ as a prognostic biomarker with a total of 368 patients, which was confirmed by an external validation cohort of 460 HNSCC patient specimens from the TCGA database. The corresponding role of this gene in regulating tumorigenesis and metastasis was also been evaluated.

PA28γ is a member of the PA28 protein family, which has been shown to bind specifically to 20S proteasomes and stimulate the hydrolysis of peptides ([@bb0040]). The PA28γ--20S proteasome pathway plays a very important role in cellular processes. Two recent studies have indicated a role for PA28γ in the regulation of the cell cycle and cell proliferation ([@bb0070], [@bb0155]). Some cellular targets of PA28γ related to the regulation of cell apoptosis have also been identified ([@bb0105], [@bb0160]). PA28γ is overexpressed in some types of cancers and has been linked with multiple cancer-related pathways ([@bb0105]). Our results indicated that PA28γ may be a tumor promoter gene that can contribute to the development of a more aggressive form of oral carcinoma. Its expression negatively correlates with patient survival. An auto-regulatory feedback loop has recently been reported between p53 and PA28γ, while a p53 mutation, which is the most comprehensive genomic characterization of HNSCC ([@bb0165]), could enhance PA28γ transcription in some cancer cells ([@bb0170]). Therefore, the prognostic significance of PA28γ may be driven by p53 mutation; this mechanism warrants further investigation.

We explored the PA28γ mRNA (gene name: PSME3) expression level in the head and neck cancer group from the TCGA database. Very few genomic changes (2 cases of mutation and 1 case of amplification in 279 head and neck squamous cell carcinoma cases) were observed, suggesting that the PA28γ contribution to oral cancer may not be through genomic events, but more likely through some local condition change events. This hypothesis is under further study in our laboratory. To date, there has been no well-established predictive model for all-cause death of patients with OSCC, or even head and neck cancer. In this study, we generated a series of basic models that included four conventional risk factors and one candidate biomarker, PA28γ. The integrated discrimination improvement was estimated when PA28γ was incorporated into different combinations of established risk factors in Models 2, 3, and 4. The incorporation of PA28γ with established risk factors improved the risk prediction for death, as shown by a substantial increase in the C Statistic. We also used an alternative model by replacement of tumor and nodal stage with clinical TNM stage in Model 3, as the latter is a more commonly used clinical prognosis factor. Thus, the role of each factor independently and in combination in predicting all-cause death could be determined. Most importantly, these models highlight the prognostic value of PA28γ by itself or in combination with conventional predictors. Our data were notable in that the replacement of multiple clinical factors with a simplified alternative clinical factor yields consistent results that would be extended to the clinical setting.

Furthermore, to evaluate the molecular basis for the clinical association described above, we investigated the biologic role of PA28γ in cancer cell lines and OSCC xenograft models. Our study provided the first biological evidence for the role of PA28γ in tumor growth and metastasis. Beyond its significance in metastasis-related outcome prediction, our data also showed that PA28γ silencing significantly suppressed tumor angiogenesis. Further studies are in progress in our laboratory.

The clinically significant role of PA28γ expression as a surrogate marker in OSCC is clearly established in this study. However, our model does have some limitations. Some reports have described prognosis according to a primary sub-site, which differs in HNSCC ([@bb0175]), the main primary sites of patients with OSCC in our cohorts were ventral tongue or floor of mouth. Although there is no difference between sub-sites in our cohorts, we could not examine survival outcomes based on PA28γ status and primary site, given the limited number of subset cases. Therefore, our data show that the use of PA28γ as a prognostic biomarker in OSCC requires more investigation before broad application in the clinical setting.

5. Conclusion {#s0020}
=============

Overall, we found that PA28γ is a good predictor of the risk of death in OSCC and adds additional information to well-established prognostic factors, which were derived from OS and DFS analyses as well as the eventual four statistic models in those cohorts. Meanwhile, the functional studies in vitro and in vivo in a mouse xenograft model also validated the cellular effects of PA28γ in OSCC. However, the molecular mechanisms responsible for its function are still unclear. The identification of the targets and action model of PA28γ in OSCC needs to be further delineated in our further study.

The following are the supplementary data related to this article.Table S1Baseline characteristics of the patients with head and neck.Table S2Univariate analyses of selected characteristics with survival among patients.Table S3Multivariate analyses of survival among patients with oral squamous cell carcinoma.Table S4Prediction of all-cause death of patients with oral squamous cell carcinoma in discovery and validation cohorts, by PA28γ and clinical factors.Fig. S1PA28γ staining pattern in both normal and tumor tissues. The staining of PA28γ in two selected tumor but not normal tissues has very clear nuclear positive, as shown by IHC assay.Fig. S2Expression of PA28γ related to carcinogenesis and prognosis in OSCC cells and human tissues. (a) Validation of PA28γ over-expression in six OSCC cells compared with normal oral keratinocyte by Western blot as described in material and methods. (b) Validation the role of PA28γ expression in OSCC prognosis in 118 clinical OSCC samples. IHC staining showed those cases with poorer prognosis exhibited stronger staining. Left: a moderate-differentiated OSCC sample with disease free survival. Middle: a well-differentiated OSCC sample with regional neck recurrence within 2 years postoperation. Right: a well-differentiated OSCC sample with cancer-related death with 4 year\'s postoperation. The scale bar represents 100 μm.Fig. S3TCGA database analysis of HNSCC patients with high and low expression of PA28γ. (a) TCGA database analysis of PA28γ mRNA abundance in human primary oral cancers compared with human normal oral tissue. (b). Kaplan--Meier plot of estimated 5-year Overall Survival time distributions according to PA28γ mRNA expression.Fig. S4Disease-Free Survival (DFS) of OSCC patients with high and low expression of PA28γ in Three cohorts defined by the Kaplan--Meier survival curves. (a) DFS in CD-I cohort. (b) DFS in CD-II cohort. (c) DFS in CD-I and -II cohorts. (d) DFS in GZ Cohort.Fig. S5ROC curves for all-cause death of OSCC patients with or without PA28γ expression in three cohorts of two independent centers. (a) ROC curve for Model 4 in CD-I and -II cohorts. (b) ROC curve for Model 4 in GZ cohort.Fig. S6PA28γ silencing induced growth inhibition of OSCC cells. (a) siRNA-003 worked the best among the three strains of siRNA against PA28γ gene expression, illustrated by qPCR, 48 h. (b) MTT assay, 48 h. PA28γ silencing inhibited the survival of OSCC cells (HSC-3, CAL-27) but not in immortalized oral keratinocytes (HOK). The percentages of surviving cells for each of two OSCC cell lines relative to controls (defined as 100% survival). All data are represented as the mean ± SD from three independent experiments (\**P* \< 0.05).Fig. S7PA28γ silencing induced apoptosis of OSCC cells. (a) PA28γ silencing induced the apoptosis in OSCC (HSC-3, CAL-27) cells, illustrated by propidium iodide (PI) assay, 48 h. Cells undergoing apoptosis and nuclear fragmentation are indicated by arrows. The scale bar represents 50 μm. All data are represented as the mean ± SD from three independent experiments (\**P* \< 0.05). (b) PA28γ silencing induced the apoptosis in OSCC (HSC-3, CAL-27) cells, as shown by TUNEL assay, 36 h. For each coverslip, ≧ 500 cells were counted. The scale bar represents 50 μm. All data are represented as the mean ± SD from three independent experiments (\**P* \< 0.05).Fig. S8PA28γ silencing decreased the migration and invasion of OSCC cells. (a) Cell migration was decreased by silencing PA28γ in OSCC cell lines (CAL-27, HSC-3), as shown by transwell migration assay, 24 h. Cells that migrated to the bottom of the chamber were counted in five fields under 20 × magnification. The scale bar represents 50 μm. Error bars mean ± SD (\**P* \< 0.05). (b) Cell invasion was decreased by silencing PA28γ in OSCC cell lines, as shown by invasion assay, 30 h (right panels, scale bars represent 50 μm). Cells that invaded to the bottom of the chamber were counted in five fields under 20 × magnification. Error bars mean ± SD (\**P* \< 0.05).Fig. S9Functional role of PA28γ on tumor growth. PA28γ-si could inhibit PA28γ expression in an OSCC xenografts model; angiogenesis in tumors was detected by CD34 staining. The average number of microvessels per vascular hot spot (mean ± SD) was significantly lower in PA28γ-si group tissues compared with those in the two control groups; Percentages of PCNA-positive nuclei (mean ± SD) in PA28γ-si group were significantly lower than those in the two control groups; Apoptosis was assessed by TUNEL assay. The scale bar represents 100 μm. (\**P* \< 0.05).
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![Overall Survival (OS) of OSCC patients with high and low expression of PA28γ in Three cohorts defined by the Kaplan--Meier survival curves. (a) Overall Survival in CD-I cohort. (b) Overall Survival in CD-II cohort. (c) Overall Survival in CD-I and -II cohorts. (d) Overall Survival in GZ cohort.](gr2){#f0010}
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![Functional role of PA28γ on the tumor growth. (a) Colony formation assay. PA28γ silencing led to colony formation inhibition in two OSCC cell lines (HSC-3 and CAL-27), after 10 days transfection with siRNA. All data are presented as the mean ± SD of three independent experiments (\**P* \< 0.05). (b) PA28γ silencing induced the apoptosis in OSCC cells, determined by Flow Cytometry assay, after 48 h transfection with siRNA. All data are presented as the mean ± SD of three independent experiments (\**P* \< 0.05). (c) Chemically-modified PA28γ-si could inhibit PA28γ gene expression in HSC-3, illustrated by qPCR, 48 h. All data are presented as the mean ± SD of three independent experiments (\**P* \< 0.05) (d ande) The tumor volumes (mean ± SD) of PA28γ-si group were significantly smaller compared to the other two groups, 30 days after injecting transfected cells. (n = 5, \**P* \< 0.05).](gr4){#f0020}

###### 

Baseline characteristics of the patients with oral squamous cell carcinoma in three cohorts.

  Characteristic                             CD-I cohort (N = 118)   CD-II cohort (N = 156)   GZ cohort (N = 94)   *P* value[⁎](#tf0005){ref-type="table-fn"}
  ------------------------------------------ ----------------------- ------------------------ -------------------- --------------------------------------------
  Age--yr (mean ± sd)                        58.97 ± 13.67           58.76 ± 10.62            60.39 ± 12.35        0.563
   \< 60 yr                                  55 (46.61)              76 (48.72)               42 (44.68)           0.821
   ≥ 60 yr                                   63 (53.39)              80 (51.28)               52 (55.32)           
  Sex                                                                                                              
   Male                                      81 (68.64)              112 (71.79)              55 (58.51)           0.089
   Female                                    37 (31.36)              44 (28.21)               39 (41.49)           
  Smoking                                                                                                          
   Never                                     65 (55.08)              76 (48.72)               50 (53.19)           0.556
   Ever                                      53 (44.92)              80 (51.28)               44 (46.81)           
  Drinking                                                                                                         
   Never                                     62 (52.54)              76 (48.72)               55 (58.51)           0.324
   Ever                                      56 (47.46)              80 (51.28)               39 (41.49)           
  Differentiation                                                                                                  
   High                                      75 (63.56)              104 (66.67)              72 (76.60)           0.144
   Moderate                                  37 (31.36)              40 (25.64)               20 (21.28)           
   Low                                       6 (5.08)                12 (7.69)                2 (2.13)             
  Primary site                                                                                                     
   Ventral tongue/floor of mouth             50 (42.37)              71 (45.51)               54 (57.45)           \< 0.001
   Buccal mucosa                             18 (15.25)              27 (17.31)               10 (10.64)           
   Gingiva                                   15 (12.71)              23 (14.74)               25 (26.60)           
   Others[a](#tf0010){ref-type="table-fn"}   35 (29.66)              35 (22.44)               5 (5.32)             
  Tumor stage                                                                                                      
   T1                                        36 (30.51)              34 (21.79)               19 (20.21)           \< 0.001
   T2                                        61 (51.69)              48 (30.77)               48 (51.06)           
   T3                                        15 (12.71)              53 (33.97)               12 (12.77)           
   T4                                        6 (5.08)                21 (13.46)               15 (15.96)           
  Nodal stage                                                                                                      
   N0                                        82 (69.49)              108 (69.23)              71 (75.53)           0.522
   N1--N3                                    36 (30.51)              48 (30.77)               23 (24.47)           
  Clinical TNM stage                                                                                               
   I                                         28 (23.73)              29 (18.59)               15 (15.93)           0.009
   II                                        45 (38.14)              37 (23.72)               38 (40.43)           
   III                                       24 (20.34)              57 (36.54)               20 (21.28)           
   IV                                        21 (17.80)              33 (21.15)               21 (22.34)           
  Surgery type                                                                                                     
   Local                                     49 (41.53)              55 (35.26)               18 (19.15)           \< 0.001
   Unilateral neck                           62 (52.54)              82 (52.56)               65 (69.15)           
   Bilateral neck                            6 (5.08)                4 (2.56)                 6 (5.32)             
   Other                                     1 (0.85)                15 (9.62)                5 (5.32)             
  Radiotherapy                                                                                                     
   Yes                                       9 (7.63)                28 (17.95)               15 (15.96)           0.044
   No                                        109 (92.37)             128 (82.05)              79 (84.04)           
  Chemotherapy                                                                                                     
   Yes                                       65 (55.08)              84 (53.85)               42 (44.68)           0.262
   No                                        53 (44.92)              72 (46.15)               52 (55.32)           
  Radiotherapy or chemotherapy                                                                                     
   Yes                                       67 (56.78)              93 (59.62)               49 (52.13)           0.512
   No                                        51 (43.22)              63 (40.38)               45 (47.87)           
  PA28γ                                                                                                            
   Low expression                            56 (47.46)              96 (61.54)               37 (39.36)           0.002
   High expression                           62 (52.54)              60 (38.46)               57 (60.64)           

Abbreviations: CD, Chengdu; GZ, Guangzhou.

*P* value of comparison between studies was generated using mixed linear model for continuous variables and chi-square test or Fisher\'s exact test for categorical variables.

Others included hard palate, mandibular and lip mucosa.

###### 

Univariate analyses of selected characteristics with survival among patients with oral squamous cell carcinoma.

  Characteristic                             CD-I cohort (N = 118)   CD-II cohort (N = 156)   GZ cohort (N = 94)                                  
  ------------------------------------------ ----------------------- ------------------------ -------------------- ---------- ------------------- ----------
  Age                                                                                                                                             
   \< 60 yr                                  0.65 (0.51--0.76)       0.510                    0.47 (0.36--0.58)    0.139      0.81 (0.66--0.90)   0.057
   ≥ 60 yr                                   0.56 (0.43--0.68)                                0.56 (0.45--0.66)               0.61 (0.46--0.73)   
  Sex                                                                                                                                             
   Male                                      0.58 (0.46--0.67)       0.327                    0.54 (0.45--0.63)    0.422      0.67 (0.52--0.78)   0.352
   Female                                    0.68 (0.50--0.80)                                0.45 (0.30--0.59)               0.74 (0.58--0.85)   
  Smoking history                                                                                                                                 
   Never                                     0.75 (0.63--0.84)       \< 0.001                 0.58 (0.46--0.68)    0.108      0.75 (0.60--0.85)   0.097
   Ever                                      0.43 (0.30--0.56)                                0.46 (0.35--0.57)               0.64 (0.48--0.76)   
  Drinking history                                                                                                                                
   Never                                     0.69 (0.56--0.79)       0.037                    0.65 (0.54--0.75)    \< 0.001   0.78 (0.65--0.87)   0.027
   Ever                                      0.52 (0.38--0.64)                                0.39 (0.28--0.49)               0.58 (0.41--0.72)   
  Cell differentiation                                                                                                                            
   High                                      0.70 (0.58--0.79)       0.003                    0.58 (0.48--0.66)    0.020      0.75 (0.63--0.83)   0.042
   Moderate or Low                           0.44 (0.29--0.58)                                0.40 (0.27--0.53)               0.55 (0.32--0.72)   
  Primary site                                                                                                                                    
   Ventral tongue/floor of mouth             0.59 (0.44--0.72)       0.814                    0.56 (0.44--0.67)    0.477      0.72 (0.58--0.82)   0.265
   Buccal mucosa                             0.67 (0.40--0.83)                                0.44 (0.25--0.62)               0.86 (0.33--0.98)   
   Gingiva                                   0.67 (0.38--0.85)                                0.43 (0.23--0.62)               0.50 (0.25--0.71)   
   Others[a](#tf0020){ref-type="table-fn"}   0.57 (0.39--0.71)                                0.54 (0.37--0.69)               0.60 (0.13--0.88)   
  Tumor stage                                                                                                                                     
   T1 or T2                                  0.66 (0.55--0.74)       0.003                    0.56 (0.45--0.66)    0.183      0.76 (0.64--0.85)   0.076
   T3 or T4                                  0.33 (0.15--0.53)                                0.47 (0.36--0.58)               0.53 (0.32--0.71)   
  Nodal stage                                                                                                                                     
   N0                                        0.72 (0.60--0.80)       \< 0.001                 0.61 (0.51--0.70)    \< 0.001   0.78 (0.67--0.86)   \< 0.001
   N1-N3                                     0.36 (0.21--0.51)                                0.31 (0.19--0.44)               0.43 (0.23--0.62)   
  Clinical TNM stage                                                                                                                              
   I or II                                   0.76 (0.65--0.85)       \< 0.001                 0.61 (0.48--0.71)    0.024      0.79 (0.66--0.88)   0.041
   III or IV                                 0.36 (0.22--0.49)                                0.46 (0.35--0.55)               0.57 (0.40--0.71)   
  Surgical method                                                                                                                                 
   Local                                     0.61 (0.46--0.73)       0.878                    0.60 (0.46--0.72)    0.116      0.78 (0.51--0.91)   0.318
   Unilateral or bilateral or other          0.60 (0.48--0.71)                                0.48 (0.38--0.57)               0.68 (0.56--0.77)   
  Radiotherapy                                                                                                                                    
   Yes                                       0.78 (0.36--0.94)       0.347                    0.43 (0.25--0.60)    0.218      1.00 (1.00--1.00)   0.008
   No                                        0.59 (0.48--0.68)                                0.54 (0.45--0.62)               0.64 (0.52--0.74)   
  Chemotherapy                                                                                                                                    
   Yes                                       0.74 (0.61--0.83)       0.002                    0.57 (0.46--0.67)    0.204      0.75 (0.58--0.86)   0.147
   No                                        0.44 (0.31--0.57)                                0.46 (0.34--0.57)               0.65 (0.51--0.77)   
  Radiotherapy or chemotherapy                                                                                                                    
   Yes                                       0.75 (0.62--0.83)       \< 0.001                 0.58 (0.47--0.67)    0.097      0.78 (0.63--0.88)   0.015
   No                                        0.42 (0.28--0.55)                                0.43 (0.31--0.55)               0.60 (0.44--0.73)   
  PA28γ                                                                                                                                           
   Low expression                            0.84 (0.71--0.91)       \< 0.001                 0.67 (0.56--0.75)    \< 0.001   0.89 (0.74--0.96)   \< 0.001
   High expression                           0.40 (0.28--0.52)                                0.28 (0.18--0.40)               0.57 (0.43--0.69)   

Abbreviations: OS, Overall Survival; CD, Chengdu; GZ, Guangzhou.

*P* value was determined using the log-rank test.

Others included hard palate, mandibular and lip mucosa.

###### 

Multivariate analyses of survival among patients with oral squamous cell carcinoma.

  Characteristic                 CD-I cohort (N = 118)   CD-II cohort 2 (N = 156)   CD cohort combined (N = 274)   GZ cohort (N = 94)                                                      
  ------------------------------ ----------------------- -------------------------- ------------------------------ -------------------- ------------------- ---------- ------------------- ----------
  Smoking history                                                                                                                                                                          
   Never                         Reference               0.072                      Reference                      0.979                Reference           0.180      Reference           0.349
   Ever                          1.87 (0.65--3.68)                                  1.01 (0.59--1.72)                                   1.32 (0.88--1.98)              1.45 (0.67--3.13)   
  Drinking history                                                                                                                                                                         
   Never                         Reference               0.717                      Reference                      0.023                Reference           0.065      Reference           0.103
   Ever                          1.14 (0.57--2.28)                                  1.86 (1.09--3.16)                                   1.47 (0.98--2.22)              1.89 (0.88--4.07)   
  Cell differentiation                                                                                                                                                                     
   High                          Reference               0.036                      Reference                      0.078                Reference           0.006      Reference           0.014
   Moderate or Low               1.98 (1.05--3.75)                                  1.55 (0.95--2.50)                                   1.70 (1.16--2.48)              2.84 (1.23--6.52)   
  Tumor stage                                                                                                                                                                              
   T1 or T2                      Reference               0.040                      Reference                      0.399                Reference           0.011      Reference           0.991
   T3 or T4                      2.20 (1.04--4.69)                                  1.23 (0.76--1.97)                                   1.65 (1.12--2.44)              1.01 (0.46--2.19)   
  Nodal stage                                                                                                                                                                              
   N0                            Reference               0.316                      Reference                      0.012                Reference           0.016      Reference           0.016
   N1-N3                         1.40 (0.72--2.72)                                  1.89 (1.15--3.10)                                   1.62 (1.09--2.40)              2.61 (1.20--5.69)   
  Radiotherapy or chemotherapy                                                                                                                                                             
   Yes                           Reference               0.004                      Reference                      0.141                Reference           0.001      Reference           0.051
   No                            2.47 (1.34--4.53)                                  1.44 (0.89--2.35)                                   1.82 (1.26--2.61)              2.17 (1.00--4.69)   
  PA28γ                                                                                                                                                                                    
   Low expression                Reference               \< 0.001                   Reference                      \< 0.001             Reference           \< 0.001   Reference           \< 0.001
   High expression               5.14 (2.51--10.5)                                  2.82 (1.73--4.61)                                   3.02 (1.05--4.43)              6.39 (2.12--19.3)   

Abbreviations: OS, Overall Survival; CD, Chengdu; GZ, Guangzhou; HR, Hazard Ratio.

*P* value was determined using Cox proportional-hazards model.

[^1]: These authors contributed equally to this work.
